Statement: Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine.
Primary_evidence: INTERVENTION 1:    No Prophylaxis   Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim. INTERVENTION 2:    Naproxen 500 mg BID   Participants received adjuvant or neoadjuvant chemotherapy and pegfilgrastim in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
Secondary_evidence: INTERVENTION 1:    Collective Placebo   Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks. INTERVENTION 2:    Pilocarpine 2 Times Per Day   Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks.